<DOC>
	<DOCNO>NCT00770328</DOCNO>
	<brief_summary>PAI-1 elevate obese individual . TNF-alpha , inflammatory mediator believe play role obesity mediate elevation PAI-1 level . TNF-alpha blockade antibody drug pentoxifylline show low PAI-1 level animal model . This study test hypothesis pentoxifylline lower PAI-1 level human subject .</brief_summary>
	<brief_title>The Effects Pentoxifylline PAI-1 Obese Population</brief_title>
	<detailed_description>Obese individual elevate PAI-1 level ( great 10 ng/ml ) randomize pentoxifylline 400mg , TID placebo 8 week . PAI-1 , TNF-a high sensitivity C-Reactive Protein measure week 0 , 4 8 .</detailed_description>
	<mesh_term>Pentoxifylline</mesh_term>
	<criteria>Inclusions : 1 . A Body Mass Index ≥ 30.0 2 . Age 21 old 3 . Few medical problem 4 . PAI1 level ≥ 10 ng/dl Exclusions : 1 . Cigarette use 2 . Present use ACE Inhibitors 3 . Recent cerebral and/or retinal hemorrhage 4 . Intolerance pentoxifylline methylxanthines caffeine , theophylline , theobromine 5 . Presently warfarin therapy 6 . Pregnancy breastfeed 7 . Recent surgery 8 . Recent diagnosis/treatment peptic ulcer</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Plasma PAI-1 level 0 , 4 , 8 week</keyword>
	<keyword>Plasma hsCRP level 0 , 4 , 8 week</keyword>
	<keyword>Plasma TNF-a level 0 , 4 , 8 week</keyword>
</DOC>